Search

Displaying results 3771 - 3780 of 10000 in total
  1. Drug

    Guar gum

    go.drugbank.com/drugs/DB13446
    Investigational

    Categories: Drugs Used in Diabetes, Compounds used in a research, industrial, or household setting
  2. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]

  3. Drug

    Evofosfamide

    go.drugbank.com/drugs/DB06091
    Investigational

    TH-302 has been shown, in preclinical studies, to be both efficacious and well tolerated. … TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide.

    Synonyms: (1-methyl-2-nitro-1H-imidazol-5-YL)methyl N,N'-bis(2-bromoethyl)diamidophosphate, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate
  4. Drug

    Acteoside

    go.drugbank.com/drugs/DB12996
    Investigational

    Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    PAC-113

    go.drugbank.com/drugs/DB05756
    Investigational

    PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. … PAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction.

  6. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  7. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. … It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

  8. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

  9. Drug

    Vecuronium

    go.drugbank.com/drugs/DB01339
    ApprovedInvestigational

    Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or

  10. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.